Evidence map›Paper›PMID 40916710›Full record

ArticleHistology and histopathology2026

CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.

Elisabeth Dingendorf, Marit Bernhardt, Isabella Federica Bollen, Tobias Kreft, Anna Katrin Scherping, Xiaolin Zhou, Manuel Ritter, Jörg Ellinger, Carsten Stephan, Glen Kristiansen

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elisabeth Dingendorf *Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Marit Bernhardt *Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Isabella Federica BollenInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Tobias KreftInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Anna Katrin ScherpingInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Xiaolin ZhouInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Manuel RitterDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Jörg EllingerDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Carsten StephanDepartment of Urology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Berlin Institute for Urologic Research, Berlin, Germany.
Glen KristiansenInstitute of Pathology, University Hospital Bonn, Bonn, Germany. glen.kristiansen@ukbonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.

methodsCD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence. In addition, CD63 expression in 251 of the 281 patients with prostate cancer was compared with CD63 expression in matched benign tissue samples (490 tissue samples). The analysis was performed automatically using the open-source software QuPath

resultsCD63 expression was found in 100% of prostate cancer cases and benign tissue spots. Increased CD63 expression was significantly associated with higher tumor stage (pT), tumor grade (ISUP), as well as shorter progression-free survival (PFS). Compared with the CD63 intensity of benign tissue, expression in tumor tissue was higher in >80% of cases. In addition, combining the expression of CD63 and AMACR, positivity reached 97.2%, making CD63 a promising diagnostic biomarker in challenging cases.

conclusionsCD63 is commonly overexpressed in prostate cancer, and higher levels are associated with earlier biochemical tumor progression; hence, CD63 is a promising diagnostic and prognostic biomarker in primary prostate cancer.

Indexed as

Biomarkers, TumorProstatic NeoplasmsTetraspanin 30AgedDisease ProgressionHumansImmunohistochemistryMaleMembrane ProteinsMiddle AgedPrognosisProstatectomyRacemases and Epimerasesalpha-methylacyl-CoA racemaseBiomarkers, TumorCD63 protein, humanMembrane ProteinsRacemases and EpimerasesTetraspanin 30

Identifiers

PMID40916710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.